WELCOME TO The PHARMACEUTICAL REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
CordenPharma | February 01, 2022
CordenPharma, a leading, full-service Contract Development & Manufacturing Organization supplying APIs, Excipients, Drug Products, and associated Packaging services, announced today the completion of the acquisition of three manufacturing facilities from Vifor Pharma, to be ultimately renamed Corden Pharma Fribourg S.A. in Switzerland, and Corden Pharma Lisbon S.A. in Portugal.
"We welcome the three sites and their employees as new members to the Cor...
Moberg Pharma | November 06, 2020
The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) ("Moberg Pharma" or "the Company") has today resolved to carry out a fully guaranteed issue of new ordinary shares and warrants ("Units") with preferential rights for existing shareholders (the "Rights Issue") of approximately SEK 150 million before transaction costs. The Rights Issue requires the approval of an extraordinary general meeting (the "Extraordinary General Meeting"). The pr...
Pfizer | December 29, 2020
After a changed, quick spreading variation of COVID-19 in the U.K. disturbed worldwide travel throughout the end of the week, an upsetting inquiry arose: Will the new antibodies from Pfizer and Moderna neutralize this startling new strain of the infection?
Presently the two organizations, alongside Pfizer's COVID-19 accomplice BioNTech, are racing to quiet an apprehensive public. They're dispatching new investigations intended to demonstrate their mRNA-based shots will fig...
Karo Pharma, Teva Pharmaceuticals | February 04, 2021
Karo Pharma Aktiebolag ("Karo") today reports the securing of an OTC brand portfolio containing Flux®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva Pharmaceuticals (Teva) for an absolute thought of EUR 84m.
The exchange moves responsibility for brand portfolio, included Flux®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva to Karo. The brands created deals barely shy of EUR 35m in 202...
BUSINESS INSIGHTS, PHARMA TECH
BUSINESS INSIGHTS, VIEWS AND ANALYSIS
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the
community for FREE